Cherney DZI, Dagogo-Jack S, McGuire DK, et al. - A recent meta-analysis of sodium–glucose cotransporter 2 (SGLT2) inhibitor outcome trials was designed to evaluate whether SGLT2 inhibitors were correlated with reduction in the risk of adverse composite kidney outcomes, with moderate heterogeneity. Researchers conducted a meta-analysis of kidney composite outcomes from the four SGLT2 cardiovascular outcome trial programs performed in general type 2 diabetes mellitus populations, which included, as a surrogate of progression to kidney failure, a sustained ≥ 40% decline in estimated glomerular filtration rate along with kidney replacement therapy and kidney death. A total of 42,516 individual participants were included; overall, 998 composite kidney events occurred. Results indicates the value of using similarly defined endpoints across trials and supports the finding of consistent protection against kidney disease progression with SGLT2 inhibitors as a class in patients with type 2 diabetes mellitus who either have established atherosclerotic cardiovascular disease or are at high cardiovascular risk with multiple cardiovascular risk factors in this meta-analysis.